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Abstract: Introdoction: Hepatitis B comprises one of the major health problems worldwide. Health Care Workers 
(HCW) are a group at risk for Hepatitis B Virus (HBV) infection. The aim of this study is Management of non-
responder health care workers to hepatitis B routine vaccination. Methods: In a descriptive-analytical study 
conducted in the Department of infectious diseases in the University Of Medical Sciences Of Tabriz, Non-responder 
cases of HCWs to HBV vaccination were studied and management. Results and Conclusions:  36.8% of HCWs 
were male and 63.3% of them were female. Mean age of male HCWs was 34.05 ± 8.58 year and in female HCWs 
was 30.43 ± 6.15 year (P<0.001). Mean of Primary response antibody titer in male HCWs was 340.59 ± 205.15 
IU/L and in female HCWs was 282.75 ± 194.22 IU/L (P=0.011). Mean of Secondary response (after one booster 
dose) antibody titer in male HCWs was 388.52 ± 175.25 IU/L and in female HCWs was 357.81 ± 164.24 IU/L 
(P=0.110). Non responder rate of HCWs for Routine vaccination (tree dose at 0,1 and 6 months)  was 31(9.36%). 
Non responder rate of HCWs after one booster dose vaccination (after tree dose at 0,1 and 6 months)  was 7(2.11%). 
Non responder rate of HCWs for secondary tree time (with double dose) vaccination (after tree dose at 0,1 and 6 
months ±  one booster dose vaccination)  was 2(0.6%).  This method seems best suited for routine immunization of 
people who give inappropriate response to routine vaccination. Those who did not respond to this method too, are 
recommended to be excluded from high risk activities in terms of exposure such as needle stick, and in case of any 
possible exposure, HBIG should be applied.  
[Varshochi M, Mohammad Shahi J. Management of non-responder health care workers to hepatitis B routine 
vaccination. Life Sci J 2012;9(4):4551-4554] (ISSN:1097-8135). http://www.lifesciencesite.com. 682 
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1. Introduction 
Viral hepatitis is one of the major 
occupational diseases among health care workers. 
Therefore, the only way to control the infection is 
application of necessary conditions to sterilize 
instruments, use of disposable gloves and needles, 
and vaccination of hospital staff to prevent the 
contamination (Hassel Horn, 1997).  
 Healthcare workers (HCWs) are more at risk 
of acquiring infection from their patients or 
transmitting various infections among their patients, 
or transferring their own infections to the patients. 
Acquisition of some of these infections causes severe 
illnesses, chronic diseases or hazardous complications 
(Jaggar, 2002; Ross, 2002). In order to reduce the 
mentioned transmission ways, the strict application of 
standard methods for preventing transmission of 
infection between patients and staff (HCWs) and their 
appropriate immunization has been recommended 
(Beltrami, 2000; Gerberding, 1995; Averhoff, 1998; 
Mahoney, 1999). 
 In medical-health centers, transmission of 
infection occurs through direct contact with blood or 
body fluids (surgery, laboratory staff, etc.), blood 
transfusion and hemodialysis (Zanetti, 2001; Koff, 
2002; Williams, 2001; Brotherton, 2003).  
 In case of HCWs, occupational exposure is a 
constant and real concern, and this risk is higher in 
the starting years of this profession. 
 Incidence of new infections of HBV among 
HCWs has been reported 1% per year (Zimmeraman, 
2003). The risk of transmission of HBV is 2,400 cases 
in every 1,000,000 surgeries, which is a high figure 
compared to HVC (140 per million) and HIV (24 
million) (Koziol and Henderson, 1996). The risk of 
transmission of HBV from HCWs to the people is 
high as well (Hasselhorn and Hofmann, 2000). 
 Unlike HIV and hepatitis C, transmission of 
HBV can be prevented by vaccination (Roggendorf 
and Viazov, 2003). This effective and safe vaccine 
was introduced and approved in 1981 (Williams, 
2001) and released in 1982 (Duclos, 2003). 
 Since 1991, injection of this vaccine in 
health centers became compulsory by WHO and other 
international organizations (Kane, 2000). This 
vaccine injected into the deltoid muscle in three doses 
and in months 0, 1 and 6 respectively (Kane, 2000), 
and over 95% of the recipients give a proper response 
to the vaccine (Roggendorf and Viazov, 2003). With 
HBV vaccination, percentage of carriers has been 
reduced from 15-20% to 1% (Duclos, 2003). 
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Regarding the wide range of HBV infection 
in the world, its serious complications and the high 
cost of treatment due to infection, the prevention of 
disease is inevitable. 
 As recommended by WHO, the groups at 
high risk, including HCWs, should be vaccinated 
against HBV. 
 After vaccination, antibodies against HBV 
are produced in the blood. Amount of the secreted 
antibodies in the blood depends on the number of 
vaccine doses and the rate of immune response of the 
body to the vaccine (Alavian, 2006). 
 When the antibody titer falls below 10 
Miu/ml, people get susceptible, and there is a 
possibility that they get infected by HBV despite 
previous vaccination. Therefore, serologic 
examination of HBs Ab and determination of 
antibody levels at regular intervals is essential in 
HCWs, and in case of reduction of antibody titer, a 
booster dose of HBV vaccine should be administered 
(Marchou, 1995). 
 In this study, we were to evaluate the 
response rate of HCWs to HBV vaccination in cases 
with inappropriate response in terms of response to 
the booster dose and double dose revaccination. 
2. Material and Methods  
In a descriptive-analytical study conducted 
in the Department of infectious diseases in the 
University Of Medical Sciences Of Tabriz, Non-
responder cases of HCWs to HBV vaccination were 
studied and management.  
 The studied HCWs are vaccinated by hepatitis B 
vaccine with fallowing properties (entitled EUVAX 
B, met the WHO requirements, made in Korea, LG 
life sciences company) for three doses (0, 1 and 6 
months) and antibody was titrated three months after 
vaccination. All utilized vaccines were from one 
brand and all tests were performed in one laboratory. 
 ELISA test was used to evaluate the samples 
used kit in this study was the Anti-HBs kit, made by 
ROCHE Company entitled “COBAS”. Methods of this 
kit was ELISA, in which ELISA micro plates in this 
method ELISA micro plates are covered by antigen S 
so that after adding serum containing antibodies against 
antigen S, antigens would bind with antibodies. In the 
next step, antigen S conjugated with peroxidase 
enzyme is added which attaches to the part of the 
antibodies not bound to antigens. Later, adding 
chromogene and substrate dies the solution whose 
color can be read by ELISA reader. 
        After performing tests and reading the plates by 
ELISA reader, standard curves were provided using 
standard samples. Later using these curves, the 
concentration of antibodies in the tested sample were 
calculated. Based on the instructions of the kit 
manufacturer, antibody level less than 10 units per mL 
was considered negative and amounts higher as 
positive. 
 In this study, HCWs vaccinated routinely 3 
times during the past 5 years on schedule (6-1-0) with 
negative HBcAB and HBsAg titers were studied in 
terms of HBsAB. 
 In this study, 331 HCWs were studied and 
those with inadequate HBsAb titers (under 10) were 
selected. These HCWs received a booster dose of HBV 
vaccine and were studied again 3 to 6 months later in 
the same laboratory in terms of HBsAb titers. 
In this study, seven HCWs under study still had 
inadequate HBsAb titers.These people underwent 3-
times double dose subcutaneous revaccination and 6 
months after vaccination, their HBsAb titers were 
evaluated. 
3. Results 
122(36.8%) of HCWs were male and 
209(63.3%) of them were female. Mean age of male 
HCWs was 34.05 ± 8.58 year and in female HCWs 
was 30.43 ± 6.15 year (P<0.001). Mean of Primary 
response antibody titer in male HCWs was 340.59 ± 
205.15 IU/L and in female HCWs was 282.75 ± 
194.22 IU/L.  Mean of Primary response antibody 
titer in male was significantly higher than female 
HCWs (P=0.011). Mean of Secondary response (after 
one booster dose) antibody titer in male HCWs was 
388.52 ± 175.25 IU/L and in female HCWs was 
357.81 ± 164.24 IU/L. 
 
 
 
 
 
 
 
 
Significant difference was not found in Secondary 
response (after one booster dose) antibody titer 
between two gender (P=0.110 
Chart 1. Non Responder Rate of HCWS at tree stage 
of Vaccination 
 
Non responder rate of HCWs for Routine 
vaccination (tree dose at 0, 1 and 6 months) was 
31(9.36%). Non responder rate of HCWs after one 
booster dose vaccination (after tree dose at 0, 1 and 6 
months) was 7(2.11%). Non responder rate of HCWs 
for secondary tree time (with double dose) 
vaccination (after tree dose at 0,1 and 6 months ±  one 
booster dose vaccination)  was 2(0.6%) (Chart 1). 
Evaluation of Age, Height and Weight of 
HCW based on primary response antibody titer were 
shown in table 1.  Evaluation of response to 
Vaccination based on Gender, Smoking and 
Hyperlipidemia were shown in table 2.  
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4. Discussions  
In the study of Hofmann et al, 2% of female 
and 1.5% of male vaccinees did not develop anti Hbs 
and 4.8% and 7.1% respectively were low responders 
(anti Hbs <100 <10 IU / l) (Hofmann, 1997).  
 In our study, out of 31 Non-Responder 
HCWs in the first stage, 10 patients (32%) were male 
and 21 (68%) were female, that in this study, non-
responsiveness was higher among females. 
 Ramos et al showed that 2 to 10% of 
healthy adults do not respond to vaccination by 
producing protective levels of antibody anti-HBs 
(assumed as protective, concentrations of ab. Anti-
HBs> 10 UI / L) (Ramos, 2000).  
 It is unclear whether booster vaccination 
of non-responders offers higher anti-HBs 
seroconversion, and hepatitis B vaccine prevents the 
infection of hepatitis B mutants in healthcare workers 
(Chen and Gluud, 2005). 
 In the study of Valats  et al, Up to 20% of 
healthcare workers are considered as non-responders 
to hepatitis B vaccination (anti-HBs<10 m UI/ml in 
serum)( Valats, 2010). 
 In our study, 36/9% of the cases under study 
were Non-Responders, similar to the results of above 
mentioned study. 
 Chlíbek et al show that the immune 
response decreases with increasing age (Chlíbek, 
2007).  
 In the study of Zeeshan et al, the percentage 
of non responders increased gradually from 9% in 
participants under 25, 13% in 25-34, 26% in 35-49, 
and 63% in ±50 years of age(Zeeshan, 2007).  
 HBsAb titer in study cases was reduced by 
increasing weight; however, this relationship was not 
statistically significant. As well, mean age of the 
study cases was higher than the others, and this 
difference was not significant. 
 Chlíbek et al demonstrated that males 
achieved lower geometric mean titres (GMT) of 
antibodies and lower seroprotectivity rates compared 
to females(Chlíbek, 2007).  
 In the study of Zeeshan et al, male non-
responders were more frequent (18%) than female 
ones (8%) (Zeeshan, 2007).  
 In our study, the rate of non-responsiveness 
in females was higher than in males, and after 
administration of the booster dose, this rate in 
females was higher than in males under study. 
 Cardell et al demonstrated that the 
seroconversion rate of protective anti-HBs level was 
68% after 3 doses and 89% after 3 or 4 
doses(Cardell, 1999).  
 In our study, the Good Responders after 
administration of 3 and 4 doses of vaccine were 
74.9% and 96.4% respectively. 
 Factors associated with a lower response 
rate in the study of Cardell et al were increasing age 
(p <0.05) and smoking (p <0.001) (Cardell, 1999).  
In our study, although the level of antibody titer in 
smokers was lower than in non-smokers, this 
difference was not statistically significant. 
 Alerany et al showed that age is the variable 
most closely linked to the risk of a poor 
immunological response (Alerany, 1993).  
 Yen et al demonstrated that being male, age 
under 40 years and positive anti-HBc are associated 
with non-responsiveness to HB vaccination (Yen, 
2005).  
 Immunized workers were more protected 
against HBV infection than non-immunized workers, 
indicating that HBV vaccine was a useful measure 
for protection against the infection (Nagao, 2008).  
Conclusions 
This method seems best suited for routine 
immunization of people who give inappropriate 
response to routine vaccination.  
Those who did not respond to this method too, are 
recommended to be excluded from high risk activities 
Table 1. Evaluation of Age, Height and Weight of HCW based on primary response antibody titer. 
 Primary Response P 
Good Responders Low Responders Non Responders 
Age(Year) 31.32 ± 7.02 32.65 ± 7.96 33.71 ± 8.51 0.146 
Height(m) 1.64 ± .08 1.64 ± .07 1.65 ± .08 0.906 
Weight(Kg) 66.28 ± 12.79 67.75 ± 14.02 69.48 ± 11.96 0.365 
 
Table 2. Evaluation of response to Vaccination based on Gender, Smoking and Hyperlipidemia 
 Sex 
P 
Smoking 
P 
Hyperlipidemia 
P 
Male Female Yes No Yes No 
Primary Response 
Non Responders 10 21 
0.158 
4 27 
0.051 
4 27 
0.989 Low Responders 15 37 3 49 6 46 
Good Responders 97 151 9 239 30 218 
Secondary 
response (after 
one booster dose) 
Non Responders 3 4 
0.123 
2 5 
<0.001 
2 5 
0.601 Low Responders 4 1 2 3 0 5 
Good Responders 115 204 12 307 38 281 
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in terms of exposure such as needle stick, and in case 
of any possible exposure, HBIG should be applied. 
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